138 related articles for article (PubMed ID: 34245252)
1. Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study.
Strange JE; Holt A; Blanche P; Gislason G; Torp-Pedersen C; Christensen DM; Hansen ML; Lamberts M; Schou M; Olesen JB; Fosbøl EL; Køber L; Rasmussen PV
Eur Heart J; 2021 Aug; 42(30):2899-2908. PubMed ID: 34245252
[TBL] [Abstract][Full Text] [Related]
2. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation.
Etminan M; Sodhi M; Ganjizadeh-Zavareh S; Carleton B; Kezouh A; Brophy JM
J Am Coll Cardiol; 2019 Sep; 74(11):1444-1450. PubMed ID: 31514945
[TBL] [Abstract][Full Text] [Related]
3. [The best of valvular heart disease in 2006].
de Gevigney G;
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():19-28. PubMed ID: 17405561
[TBL] [Abstract][Full Text] [Related]
4. Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes.
Rawshani A; Sattar N; McGuire DK; Wallström O; Smith U; Borén J; Bergström G; Omerovic E; Rosengren A; Eliasson B; Bhatt DL; Rawshani A
Circulation; 2022 Aug; 146(5):398-411. PubMed ID: 35678729
[TBL] [Abstract][Full Text] [Related]
5. Association Between Use of Fluoroquinolones and Risk of Mitral or Aortic Valve Regurgitation: A Nationwide Cohort Study.
Dong YH; Wang JL; Chang CH; Lin JW; Chen YA; Chen CY; Toh S
Clin Pharmacol Ther; 2024 Jan; 115(1):147-157. PubMed ID: 37926942
[TBL] [Abstract][Full Text] [Related]
6. Associations of aortic and mitral regurgitation with body composition and myocardial energy expenditure in adults with hypertension: the Hypertension Genetic Epidemiology Network study.
Palmieri V; Bella JN; Arnett DK; Oberman A; Kitzman DW; Hopkins PN; Rao DC; Roman MJ; Devereux RB;
Am Heart J; 2003 Jun; 145(6):1071-7. PubMed ID: 12796765
[TBL] [Abstract][Full Text] [Related]
7. Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study.
Başaran Ö; Dogan V; Beton O; Tekinalp M; Aykan AÇ; Kalaycıoğlu E; Bolat I; Taşar O; Şafak Ö; Kalçık M; Yaman M; İnci S; Altıntaş B; Kalkan S; Kırma C; Biteker M;
J Thromb Thrombolysis; 2017 Feb; 43(2):157-165. PubMed ID: 27848065
[TBL] [Abstract][Full Text] [Related]
8. Long-term Cardiovascular Adverse Events Induced by Fluoroquinolones: A Retrospective Case-control Study.
Algaidi SH; Alghamdi DI; Algheffari SG; Alzahrani RA; Thabit AK; Hafiz AM
J Cardiovasc Pharmacol; 2023 Nov; 82(5):400-406. PubMed ID: 37506675
[TBL] [Abstract][Full Text] [Related]
9. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
10. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Valve Disease and Prevalent and Incident CKD in Community-Dwelling Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study.
Karandikar VM; Honda Y; Ishigami J; Lutsey PL; Hall M; Solomon S; Coresh J; Shah A; Matsushita K
Kidney Med; 2022 Dec; 4(12):100559. PubMed ID: 36483991
[TBL] [Abstract][Full Text] [Related]
12. Echocardiographic assessment of mitral stenosis and its associated valvular lesions in 205 patients and lack of association with mitral valve prolapse.
Sagie A; Freitas N; Chen MH; Marshall JE; Weyman AE; Levine RA
J Am Soc Echocardiogr; 1997 Mar; 10(2):141-8. PubMed ID: 9083969
[TBL] [Abstract][Full Text] [Related]
13. Regurgitant valvular disease prevalence and progression found on echocardiogram in military aviators.
Davis SM; Davenport ED; Haynes JT; Alvarado RL
Aviat Space Environ Med; 2014 Oct; 85(10):1013-8. PubMed ID: 25245901
[TBL] [Abstract][Full Text] [Related]
14. Elevated blood pressure and risk of mitral regurgitation: A longitudinal cohort study of 5.5 million United Kingdom adults.
Rahimi K; Mohseni H; Otto CM; Conrad N; Tran J; Nazarzadeh M; Woodward M; Dwyer T; MacMahon S
PLoS Med; 2017 Oct; 14(10):e1002404. PubMed ID: 29040269
[TBL] [Abstract][Full Text] [Related]
15. Valvular heart disease: the influence of changing etiology on nosology.
Boudoulas H; Vavuranakis M; Wooley CF
J Heart Valve Dis; 1994 Sep; 3(5):516-26. PubMed ID: 8000586
[TBL] [Abstract][Full Text] [Related]
16. Implications of third heart sounds in patients with valvular heart disease. The Veterans Affairs Cooperative Study on Valvular Heart Disease.
Folland ED; Kriegel BJ; Henderson WG; Hammermeister KE; Sethi GK
N Engl J Med; 1992 Aug; 327(7):458-62. PubMed ID: 1625735
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
J Am Coll Cardiol; 1999 Dec; 34(7):2088-95. PubMed ID: 10588229
[TBL] [Abstract][Full Text] [Related]
18. Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study.
Nazarzadeh M; Pinho-Gomes AC; Smith Byrne K; Canoy D; Raimondi F; Ayala Solares JR; Otto CM; Rahimi K
JAMA Cardiol; 2019 Aug; 4(8):788-795. PubMed ID: 31290937
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
20. [Current surgical treatment for acquired valvular heart disease].
Ueno T; Sakata R
Nihon Geka Gakkai Zasshi; 2008 Jul; 109(4):194-200. PubMed ID: 18681163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
